Gossamer Bio, Inc.
GOSSDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 4, 2026
21dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
How GOSS's past catalysts played out
GB001
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
GB002 (seralutinib)
Pulmonary Artery Hypertension
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
GB001 | Phase 2 | Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) | - | - |
GB002 (seralutinib) | Phase 2 | Pulmonary Artery Hypertension | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Gossamer Bio, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Gossamer Bio, Inc.'s (GOSS) pipeline across Phase 2. Its lead program is GB001 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Gossamer Bio, Inc.'s next FDA catalyst?→
Gossamer Bio, Inc.'s (GOSS) next tracked catalyst is a Earnings expected August 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track GOSS biotech catalysts?→
Add GOSS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Gossamer Bio, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.